WEE1 INHIBITORS AND METHODS FOR TREATING CANCER

Disclosed herein is a method of determining subject sensitivity to a WEE1 inhibitor, comprising obtaining or having obtained a biological sample from the subject, and performing or having performed at least one assay on the biological sample to determine if the subject has an altered DNA repair func...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SAMATAR, Ahmed, SUN, Anthony, DONATE, Fernando, BUNKER, Kevin, HUANG, Peter, PULTAR, Philippe, TOLCHER, Anthony, RUDOLF DE JONG, Petrus, VOLIOTIS, Dimitrios
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Disclosed herein is a method of determining subject sensitivity to a WEE1 inhibitor, comprising obtaining or having obtained a biological sample from the subject, and performing or having performed at least one assay on the biological sample to determine if the subject has an altered DNA repair function of NBN, MRE11, RAD50 or MRE11-RAD50-NBN (MRN) protein complex. Also disclosed are methods of treating cancer with WEE1 inhibitors, and modifying the effective concentration based upon the sequence variation and function of NBN, MRE11, RAD50 or MRE11-RAD50-NBN (MRN) protein complex. La présente invention concerne un procédé pour déterminer la sensibilité d'un sujet à un inhibiteur de WEE1, comprenant l'obtention ou avoir obtenu un échantillon biologique provenant du sujet, et la réalisation ou avoir réalisé au moins un dosage sur l'échantillon biologique pour déterminer si le sujet présente une fonction altérée de réparation de l'ADN de NBN, MRE11, RAD50 ou du complexe protéique MRE11-RAD50-NBN (MRN). La présente invention concerne également des méthodes de traitement du cancer avec des inhibiteurs de WEE1, et la modification de la concentration efficace en fonction de la variation de la séquence et de la fonction de NBN, MRE11, RAD50 ou du complexe protéique MRE11-RAD50-NBN (MRN).